Cessatech (CESSA) Q2 2025 earnings summary

Executive summary

• Achieved positive and clinically meaningful top-line results from pivotal Study 0202, supporting regulatory submissions and future commercialization.

• US manufacturing technology transfer for CT001 is nearing completion, positioning for a US launch by year-end.

• CT001 dossier for EMA submission was filed and validated on 14 August, with potential approval expected in 2026.

• Strengthened leadership with the promotion of Martin Juhl to Executive Management and completed a DKK 14.6 million capital raise.

Financial highlights

• Q2 2025 net revenue was DKK 1,243k, with an operating loss of DKK -3,554k and net loss of DKK -2,785k.

• Cash at bank at period end was DKK 15,051k, bolstered by a direct share issue.

• Earnings per share for Q2 2025 was DKK -0.16.

• Operating costs decreased compared to Q2 2024, reflecting lower development expenses as CT001 nears completion.

Outlook and guidance

• Initiation of the US Early Access Program for CT001 is expected to significantly improve future revenue potential.

• Remaining 2025 development costs are expected to decrease as major clinical and CMC activities conclude.

• Cash position is considered sufficient for upcoming periods, excluding a loan facility and tax return due in Q4 2025.